Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NQO1 | P15559 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.34 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.34 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30193576 | 0.78 | KMT2A (0.50) | CA12CA9KMT2ADAOMCL1 | |
| SCHEMBL4912683 | 0.78 | KMT2A (0.50) | CA12CA9KMT2ADAOMCL1 | |
| SCHEMBL670199 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2CA12CA9CYP1A2CYP2A6 | |
| SCHEMBL30728018 | 0.76 | HTR2A (0.39) | SMN1; SMN2CYP1A2VCPKDM4EALDH1A1 | |
| SCHEMBL1054636 | 0.74 | SMN1; SMN2 (0.58) | SMN1; SMN2NQO1KMT2ADAONPC1 | |
| SCHEMBL27407574 | 0.74 | SMN1; SMN2 (0.48) | SMN1; SMN2KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL5642556 | 0.73 | SMN1; SMN2 (0.42) | SMN1; SMN2CA12CA9CYP1A2CYP2A6 | |
| SCHEMBL3969742 | 0.73 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP1A2CYP2A6KMT2ABACE1 | |
| Dimethylamine SCHEMBL11499079 | 0.73 | KMT2A (0.46) | CA12CA9KMT2ADAOMCL1 | |
| SCHEMBL11747741 | 0.73 | KMT2A (0.59) | SMN1; SMN2CA12CA9KMT2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-10 | — | — | US | disclosed |
| US-20180297983-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-10-18 | — | — | US | disclosed |
| CN-101500563-B | Cycloalkanopyrolocarbazole derivatives and the use thereof as PARP, VEGFR2 and MLK3 inhibitors | CEPHALON INC | 2015-05-06 | — | — | CN | disclosed |
| CN-104230786-A | Indole-structure-containing compound with anti-tumor activity and synthesis method thereof | UNIV SHAANXI SCIENCE & TECH | 2014-12-24 | — | — | CN | disclosed |
| CN-101500563-A | Cycloalkanopyrolocarbazole derivatives and the use thereof as PARP, VEGFR2 and MLK3 inhibitors | CEPHALON INC (US) | 2009-08-05 | — | — | CN | disclosed |
| WO-2005026216-A1 | PROCESS FOR THE PRODUCTION OF THIN FILMS OF MELANIN AND MELANIN-LIKE MOLECULES BY ELECTROSYNTHESIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-03-24 | — | — | WO | disclosed |
| US-5721347-A | Esters and amides of substituted pyrrole acetic acids | CELL PATHWAYS, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| US-5130308-A | Indole derivatives as anticarcinogenic agents | ASTA PHARMA (DE) | 1992-07-14 | — | — | US | disclosed |
| EP-0485157-A2 | Esters and amides of substituted pyrrole acetic acids | FGN, INC. (US) | 1992-05-13 | — | — | EP | disclosed |
| US-4992553-A | Treatment of hormone dependent tumors | ASTA PHARMA AKTIENGESELLSCHAFT (DE) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297983-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | PADI4, PADI1, PADI2 | SMN1; SMN2 4198/4885CA12 2132/4885CA9 1288/4885 |
| US-10407407-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | SMN1; SMN2 4198/4885CA12 2132/4885CA9 1288/4885 |
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | HTR5A, HTR2C, TPH1 | SMN1; SMN2 2830/4885CA12 4877/4885CA9 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.